TABLE 4.
A summary of current erosolized polymeric NP formulations targeting EMT-markers in the literature.
| NP | API(s) | Disease | Model(s) | Effects | Ref |
|---|---|---|---|---|---|
| Poly (ethylenimine) (PEI-C) polyplex | siPAI-1 | Pulmonary fibrosis (PF) | PF mice | Inhibition of PAI-1 and TGF-β, decreased collagen deposition in lungs | Ding et al. (2018), Wang Y. et al. (2019) |
| Perfluorocarbon (PFC) nanoemulsion | CXCR4 antagonist + anti-STAT3 siRNA | Lung metastasis | 4T1.Luc mice | Inhibition of VEGF, decreased tumor growth and increased survival | Li et al. (2019) |
| Poly (ɛ-caprolactone) (PCL) | Pirfenidone | Pulmonary fibrosis (PF) | A549 cells | Inhibition of TGF- β1 mRNA and EMT | Singh et al. (2019) |
| PEG-PCC-g-DC micelles | MDB5 | Liver fibrosis | CBDL mice | Inhibition of hh activity, HSC activation, and decreased collagen deposition | Kumar et al. (2019) |
| Pluronic F127 (PM) micelles | Salinomycin (SAL) | Lung cancer | A549 cells | Inhibition of VIM and EMT, reduced cell migration | Sousa et al. (2019) |
| PEG-PLL-PLLeu Polypetide micelles | ZEB1 siRNA + doxorubicine | Non-small cell lung cancer | H460 mice | Inhibition of EMT and metastasis | Fang et al. (2014) |
| CMD-chitosan nanoparticles | siRNA + doxorubicin | Lung cancer | A549 cells | Inhibition of EMT markers, reduced cell migration | Seifi-Najmi et al. (2016) |
| EGFR-conjugated gelatin nanoparticles | siRNA | Non-small cell lung cancer | H820 + H1975 cells | Inhibition of Vimentin, N-Cadherin, and EMT | Suresh et al. (2019) |